Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 8/20 | 0.61 |
| ▸ | DHODH | Q02127 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.52 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275722 | 0.91 | ACLY (0.57) | ACLYDHODHKDM4EPOLBNPC1 | |
| SCHEMBL1317226 | 0.89 | ACLY (0.56) | ACLYDHODHHPGDKDM4EALDH1A1 | |
| SCHEMBL27970823 | 0.85 | HPGD (0.64) | DHODHHPGDKDM4EALDH1A1POLB | |
| SCHEMBL2272508 | 0.84 | ACLY (0.63) | ACLYDHODHALDH1A1HDAC1SUCNR1 | |
| SCHEMBL27743215 | 0.84 | SLC16A3 (0.56) | HPGDKDM4EALDH1A1POLBRAB9A | |
| SCHEMBL2272453 | 0.84 | ACLY (0.63) | ACLYDHODHHPGDKDM4EALDH1A1 | |
| SCHEMBL8252530 | 0.83 | ALDH1A1 (0.72) | DHODHHPGDKDM4EALDH1A1POLB | |
| SCHEMBL2269604 | 0.83 | ACLY (0.69) | ACLYDHODHHPGDSUCNR1 | |
| SCHEMBL5145099 | 0.83 | ACLY (0.61) | ACLYDHODHNPC1RAB9AHDAC1 | |
| SCHEMBL2278464 | 0.83 | ACLY (0.49) | ACLYDHODHKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885DHODH 1469/4885HPGD 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.